Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1

Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1

Abstract The existing repertoire of HIV-1 patient derived broadly neutralising antibodies (bNAbs) that target the HIV-1 envelope glycoprotein (Env) present numerous and exciting opportunities for immune-based therapeutic and preventative strategies against HIV-1. Combination antibody therapy is requ...

Full description

Bibliographic Details
Main Authors: Tumelo Moshoette, Stuart Alvaro Ali, Maria Antonia Papathanasopoulos, Mark Andrew Killick
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Retrovirology
Subjects:
HIV-1 prevention
HIV-1 therapy
Broadly neutralizing antibodies
Bispecific antibodies
Online Access:http://link.springer.com/article/10.1186/s12977-019-0493-y

Internet

http://link.springer.com/article/10.1186/s12977-019-0493-y

Similar Items